ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase II Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata

A Phase II proof-of-concept trial of farudodstat inAlopecia areata is expected to start enrolling patients in the United States in the second quarter of 2023.